Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance
Interventions
Daratumumab and hyaluronidase-fihj
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Edicotinib, Pharmacokinetic Study
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Daratumumab/rHuPH20
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
837
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
Active, not recruiting No phase listed Observational

Brigham and Women's Rheumatoid Arthritis Sequential Study

NCT01793103
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Depot Risperidone Microsphere (Consta)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Butner, North Carolina
Conditions
HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Buffalo, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Glucose Regulation During Risperidone and Olanzapine Treatment

NCT00006195
Conditions
Schizophrenia
Interventions
risperidone, olanzapine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer
Interventions
Daratumumab, KRAS vaccine, Nivolumab
Drug · Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
risperidone, quetiapine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Completed Phase 2Phase 3 Interventional Results available

Pharmacogenomics in Autism Treatment

NCT00584701
Conditions
Autism
Interventions
Risperidone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Alzheimer Disease
Interventions
Galantamine
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 47 more
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Diclazuril
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial

NCT00133822
Conditions
Post-Traumatic Stress Disorders
Interventions
Sertraline and Risperidone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Diclazuril
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
12 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York
Conditions
Atrial Fibrillation, Stroke
Interventions
Alert-based computerized decision support
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Thalidomide, Dexamethasone, Daratumumab, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, Melphalan, ASCT, Lenalidomide, Bortezomib
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Acute Lymphoblastic Leukemia
Interventions
Ibrutinib, Dasatinib, Prednisone
Drug
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Schizophrenia, Bipolar Disorder, Depression
Interventions
Using Medications Effectively
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Nashua, New Hampshire
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Interventions
Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101
Drug · Radiation
Lead sponsor
Robert Lowsky
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Schizophrenia
Interventions
Risperidone, divalproex
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, CD20 Positive, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide, Rituximab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Not listed
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
192
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 162 more